Valion Bio VBIO Income Statement (2021-2026)

NASDAQ VBIO
$2.20 -0.20 (-8.33%)
At close: Sep 10, 2026 · 4:00 PM EDT
Reported Financials

Valion Bio Quarterly Income Statement

Periods 21 quarters
Latest Jun 2026

Valion Bio reported revenue of $0.04M for the quarter ended Jun 2026, down 44.3% year over year. This income statement covers 21 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Revenue & cost
Revenue
0.27M0.28M0.39M0.43M0.53M0.48M0.41M0.38M0.16M0.28M0.36M0.33M0.14M0.13M0.18M0.07M0.09M0.15M0.08M0.04M
Cost of RevenueCost of Rev
0.30M0.30M0.39M0.36M0.40M0.41M0.36M0.26M0.10M0.17M0.35M0.17M0.11M0.08M0.42M0.02M0.03M0.29M0.01M0.01M
Gross Profit
-0.03M-0.03M-0.00M0.07M0.12M0.06M0.04M0.11M0.06M0.11M0.01M0.17M0.03M0.04M-0.24M0.05M0.05M-0.14M0.07M-0.04M
Operating items
Research & DevelopmentR&D
0.34M0.45M0.69M0.68M1.12M0.49M0.50M0.49M0.47M0.48M0.73M0.51M0.30M0.42M0.33M0.34M0.66M0.86M
Selling, General & AdministrativeSG&A
0.48M0.58M1.28M1.23M1.52M1.76M1.36M1.28M1.27M1.05M1.15M0.89M0.79M0.82M0.67M1.04M0.91M1.06M
Other Operating ExpensesOther Opex
0.19M0.17M0.31M0.40M0.50M0.40M0.43M0.46M0.45M0.34M0.36M0.26M0.21M0.24M0.18M0.43M-0.12M
Operating ExpensesOpex
1.02M1.20M2.29M2.31M3.14M2.65M2.30M2.23M2.19M1.87M2.25M1.65M1.30M1.48M1.24M1.56M1.99M2.34M
Operating IncomeOp. Inc
-1.05M-1.23M-2.29M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.27M-1.43M-1.48M-1.51M-1.93M-2.48M
EBIT
-1.05M-1.23M-2.29M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.27M-1.43M-1.48M-1.51M-1.93M-2.48M
Non-operating items
Non Operating Interest Expenses
0.22M0.06M
Interest & Investment IncomeInt & Inv Inc
0.00M
Other Non Operating IncomeOther Non Op Inc.
0.16M0.08M-1.79M-0.00M
Non Operating IncomeNon Op. Inc.
-0.04M-1.09M-1.43M0.00M0.00M-0.06M0.01M0.00M0.00M-0.11M
Net income details
EBT
-1.28M-1.23M-2.29M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.33M-1.43M-1.48M-1.51M-1.93M-2.48M
Profit After TaxPAT
-1.09M-2.32M-3.72M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.27M-1.43M-1.50M-1.50M-1.93M-2.60M
Income from Continuing OperationsIncome (Continuing)
-1.28M-1.23M-2.29M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.33M-1.43M-1.48M-1.51M-1.93M-2.48M
Consolidated Net IncomeConsol Net Inc.
-1.28M-1.23M-2.29M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.33M-1.43M-1.48M-1.51M-1.93M-2.48M
Income towards Parent CompanyParent Net Inc
-1.28M-1.23M-2.29M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.33M-1.43M-1.48M-1.51M-1.93M-2.48M
Net Income towards Common StockholdersNet Income
-1.28M-1.23M-2.29M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.33M-1.43M-1.48M-1.51M-1.93M-2.48M
Additional items
EPS (Basic)
-13.46-11.92-16.40-5.76-7.84-667.53-582.80-262.89-179.01-36.98-70.74-25.23-8.27-5.78-129.01-63.13-54.86-46.92
EPS (Diluted)
-13.46-11.92-16.40-5.76-7.84-6.68-5.83-262.89-179.01-36.98-70.74-25.23-8.27-5.78-129.01-63.13-54.86-70.32
Shares Outstanding
0.09M0.10M0.14M0.39M0.38M0.00M0.00M0.01M0.01M0.05M0.03M0.06M0.16M0.25M0.01M0.02M0.04M0.05M0.05M0.14M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.09M0.10M0.14M0.39M0.38M0.39M0.39M0.01M0.01M0.05M0.03M0.06M0.16M0.25M0.01M0.02M0.04M0.04M0.04M0.04M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.09M0.11M0.14M0.39M0.38M0.00M0.00M0.01M0.01M0.05M0.03M0.06M0.16M0.25M0.01M0.03M0.04M0.05M0.05M0.14M
EBITDA
-1.05M-1.23M-2.29M-2.24M-3.02M-2.58M-2.26M-2.12M-2.12M-1.76M-2.24M-1.48M-1.27M-1.43M-1.48M-1.51M-1.93M-2.48M
Interest ExpensesInt Expense
0.22M0.06M